An interventional study of Mediterranean diet and Mediterranean diet + functional foods in Metabolic Syndrome, sponsored by Dr. Schär AG / SPA. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Metabolic Syndrome with a site in Italy — 16 open to participants now, 18 under way, none of them phase 3. Metabolic Syndrome · Italy.
Among the 95 studies in Metabolic Syndrome with a site in Italy, this one is the 48th largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 92nd registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →16 of the 95 studies in Metabolic Syndrome with a site in Italy are open now. Recruiting first, the newest first:
Catholic University of the Sacred Heart · Sites in Italy
Ages 18+
Catholic University of the Sacred Heart · Sites in Italy
Ages 18–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–80
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 13–18
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 7 · Phase 4 9
First in 1996; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 71 across the 62 interventional studies, 200 across the 33 observational. Of the 59 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 95 have an industry lead sponsor. The 10 most frequent:
Dr. Schär AG / SPA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Dr. Schär AG / SPA has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Metabolic Syndrome with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06801769Catholic University of the Sacred HeartStudy for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells. | 2026-12 |
| NCT07155473Fondazione Policlinico Universitario Agostino Gemelli IRCCSIdentification of a Score for the Assessment of Intrapancreatic Fat | 2026-12 |
| NCT05781269Istituto Auxologico ItalianoLong Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART) | 2026-12-31 |
| NCT06647108ESIFood Supplement for Individuals with Metabolic Syndrome | 2027-01 |
| NCT07505277Dr. Schär AG / SPAStudy of the Effects of Food Formulations Containing Antioxidants, Prebiotic Fibers, and Oat Beta-glucans in Individuals at Risk of Metabolic Syndrome | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 95 studies in Metabolic Syndrome with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether introducing specific functional foods into the diet of individuals at risk of developing metabolic syndrome leads to improvements in key metabolic and oxidative health parameters.
The main questions it aims to answer are:
Does the consumption of these functional foods reduce post-prandial glycemia? Does daily intake of these formulations improve other health indicators such as body weight, body composition, lipid profile, and oxidative metabolomic markers?
The functional food formulations used in this study include:
A blend of multifunctional ingredients derived from apple and grape by-products Added prebiotic fibers (inulin) Oat β-glucans Omega-3 fatty acids
Participants will:
Consume the assigned functional food formulations daily Attend regular clinic visits for physiological measurements and blood tests Undergo assessments of body composition, serum lipids, and serum metabolomics
Primary Study Objective:
Variation in post-prandial glycemia
Secondary Objectives:
Reduction in BMI Changes in body composition Changes in serum lipid profile Changes in serum oxidative-related metabolomics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard diet for 8 weeks, followed by the introduction of functional foods for an additional 8 weeks
Other: Mediterranean diet and Mediterranean diet + functional foods
1. PHASE: Mediterranean diet for 8 weeks 2. PHASE: Mediterranean diet + functional foods for 8 weeks
Changes in postprandial glycemia
Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Changes in BMI
Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Changes in body composition
Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Changes in serum lipid profile
Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Changes in serum oxidative related metabolomics
Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.
Of 50 industry-sponsored interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 12 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Schär AG / SPA